Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ）

This is a Phase 3, prospective, randomized, open-label, multi-center study that assesses the efficacy and safety of neoadjuvant therapy with different cycles of sintilimab combined with chemotherapy for Resectable Squamous Cell NSCLC. This trial will also explore the biomarkers of neoadjuvant immunochemotherapy.

Trial Details

NCT ID
NCT05429463
Phase
PHASE3
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Sintilimab
  • Carboplatin
  • Albumin-Bound Paclitaxel
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Sign the informed consent form before starting any trial related procedure.Be willingness and able to undergo planned visits, protocol therapy, lab…
  • 18-75 years old, male or female.
  • Squamous Cell Non-small cell lung cancer confirmed by cytology or histology.
  • There must be at least one evaluable focus judged according to recist1.1 standard.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →